Unity Biotechnology Unites with Ascentage Pharma

Date Posted:
Apr 26, 2016

Unity Biotechnology, a startup cofounded by Buck Institute faculty member Judith Campisi, has announced a collaboration with Ascentage Pharma, a global, China-based clinical-stage biopharmaceutical company, have announced a worldwide collaboration to develop senolytic treatments for age-related disease. “We chose Ascentage as our partner in this exciting anti-aging field not only because of its cutting-edge technology, but also because this partnership will allow us to reach a global market,” noted Unity founder and CEO Dr. Nathaniel David.

For more information, please visit the Unity Biotechnology website.